Kumar Neil sold 14,602 shares of BridgeBio Pharma, Inc. at $82.99 for −$1.21M on Aug 18, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed Aug 20, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$1,211,852.10Shares × reported price
Shares traded
14,602Common Stock
Price per share
$82.99Reported price. Read footnotes for ranges.
% of reported position traded
5.64%This security and ownership context
Holdings after
244,526Direct
Trade date
Aug 18, 2026Sell
Filed
Aug 20, 2026, 4:31 PM ET2-day reporting delay
Accession
0001470831-26-000848Code S · Transaction 13051
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 259,128 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 18, 2026Sell1,900$81.15−$154,183.86Trade 13049
Aug 18, 2026Sell17,279$82.21−$1,420,513.50Trade 13050
Aug 18, 2026Sell1,199$83.77−$100,444.07Trade 13052
Aug 19, 2026Sell8,100$83.86−$679,256.28Trade 13053
Aug 19, 2026Sell1,800$84.69−$152,436.06Trade 13054
Aug 19, 2026Sell100$85.65−$8,565Trade 13055
7 transaction rows in this filing. Joint filers share the same rows.

BBIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BBIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −1.9%1w ago +0.9%1d ago −3.7%
Returns since7d −4.3%30d −20%90d180d1y

Footnotes in full

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F2: Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F4: Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F5: Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F6: Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F7: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. F8: Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F9: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.